Von Hippel-Lindau Disease Genetic Epidemiology Study
Von Hippel-Lindau (VHL) Disease Genetic Epidemiology Study
Sponsor: National Cancer Institute (NCI)
Terminated
IRB approval lapsed and PI has not responded to requests to submit CR.
Other terminated trials from National Cancer Institute (NCI)
This observational or N/A phase trial investigates Kidney Neoplasms and Von Hippel Lindau Disease and is currently terminated or withdrawn. National Cancer Institute (NCI) leads this study, which shows 13 recorded versions since 1999 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Terminated
-
Jul 2024 — Sep 2024 [monthly]
Terminated
-
Jan 2021 — Jul 2024 [monthly]
Terminated
-
Feb 2020 — Jan 2021 [monthly]
Terminated
Status: Unknown Status → Terminated
-
Oct 2019 — Feb 2020 [monthly]
Unknown Status
Status: Active Not Recruiting → Unknown Status
▶ Show 8 earlier versions
-
Aug 2019 — Oct 2019 [monthly]
Active Not Recruiting
-
Jul 2019 — Aug 2019 [monthly]
Active Not Recruiting
-
Jun 2019 — Jul 2019 [monthly]
Active Not Recruiting
-
May 2019 — Jun 2019 [monthly]
Active Not Recruiting
-
Sep 2018 — May 2019 [monthly]
Active Not Recruiting
-
Jun 2018 — Sep 2018 [monthly]
Active Not Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Active Not Recruiting
Phase: NA → None
-
Jan 2017 — Apr 2018 [monthly]
Active Not Recruiting NA
First recorded
Feb 1999
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .